抗凝血薬(経口抗凝血薬、注射用抗凝血薬、未分画ヘパリン、低分子ヘパリン)の世界市場

◆英語タイトル:Anticoagulants (Oral Anticoagulants, Injectable Anticoagulants, Unfractionated Heparin, Low Molecular Weight Heparin) : Global Strategic Business Report
◆商品コード:GIA60174
◆発行会社(調査会社):Global Industry Analysts
◆発行日:2016年1月
◆ページ数:267
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Single User(DRM付き)USD4,950 ⇒換算¥564,300見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Industry Analysts社の日本における正規販売代理店です。Global Industry Analysts社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、抗凝血薬(経口抗凝血薬、注射用抗凝血薬、未分画ヘパリン、低分子ヘパリン)の世界市場について調査・分析し、抗凝血薬(経口抗凝血薬、注射用抗凝血薬、未分画ヘパリン、低分子ヘパリン)の世界市場規模、市場動向、市場予測、関連企業情報などをお届けいたします。
【レポートの概要】

This report analyzes the worldwide markets for Anticoagulants in US$ Million by the following Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 51companies including many key and niche players such as –
Abbott India Limited
Aspen Holdings
Bayer Healthcare AG
Boehringer Ingelheim
Bristol-Myers Squibb Company

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

【レポートの目次】

I. INTRODUCTION, METHODOLOGY &PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Oral Anticoagulants
Injectable Anticoagulants
II. EXECUTIVE SUMMARY
1. GLOBAL MARKET OVERVIEW
Anticoagulants Market Driven by Novel Oral Anti-coagulants
Safety Issues Associated with Erstwhile Market Leaders – Warfarin & Heparins
Anticoagulants – Evolution from Injectables to Oral Drugs
Conventional Oral Drugs Face the Heat
The Newer Breed of NOACs
Comparative Analysis of Warfarin and Novel Oral Anticoagulants
Table 1: Global Market for Leading Oral Drugs (2014): Percentage Market Share Breakdown of ValueSales for Eliquis, Pradaxa, Xarelto, and Others(includes corresponding Graph/Chart)
Novel Oral Drugs: Absence of Antidote & Other Concerns
Rapid Ongoing R&D on Antidote Development
Pipeline of Antidotes to Reverse Anticoagulant Action
Aging Population: Crucial Driver for Anticoagulants Market
Table 2: Global Population Statistics for65+ Age Group (2014) (includes corresponding Graph/Chart)
Table 3: Elderly Population (65+ Years) Worldwideby Geographic Region on the Basis of EconomicStatus (2000 & 2025): % of Total Population forMore Developed Countries, Less DevelopedCountries and Least Developed Countries(includes corresponding Graph/Chart)
Table 4: Life Expectancy for Select Countries inNumber of Years (2015E) (includes corresponding Graph/Chart)
Rising Stroke Statistics – An Opportunity Indicator for Anticoagulants
Global Menace of Cardiovascular Disease – Major Growth Factor
Table 5: Global Annual Medical Cost of CVD inUS$ Billion (2010-2030) (includes corresponding Graph/Chart)
Table 6: Fatalities by Heart Conditions – Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others(includes corresponding Graph/Chart)
Sizing the Market
No Immediate Threat of Generics for NOACs
Market Players
Betrixaban – The Only Other Novel Oral Drug in Pipeline
2. MARKET TRENDS & ISSUES
NICE Guidelines Promote NOAC Usage
NOACs as Alternative/Supplement to Antiplatelet Therapy
Increase in Heparin Trade Boosts the Market
NOAC Underdosing Trend Restrains Universal Acceptance
Generics Prevail in the Traditional Market
Patent Expiries of Traditional Anticoagulants in the US
Inadequate Trials Mar Pediatric Anticoagulants Market
Growing Demand for Self-Testing
LMWHs Ease Outpatient Management
3. SEGMENT ANALYSIS
Oral Anticoagulant Agents
Traditional Oral Anticoagulants
Warfarin
Coumadin – The Branded Warfarin
Advantages and Alternatives
Side Effects
Limitations
Novel Oral AntiCoagulants (NOAC)
Approved Indications of Various NOACs by Geographic Region
Approved Anticoagulant Agents in a Nutshell
Pradaxa (Dabigatran Etexilate)
Pradaxa and Warfarin – A Comparative Study
Xarelto (Rivaroxaban)
Apixaban (Eliquis)
Injectable Anticoagulants
Injectable Anticoagulants- An Insight
Heparin – The Backbone of Injectable Anticoagulants
Unfractionated Heparin
Advantages and Alternatives
Limitations
Low Molecular Weight Heparins
Indications
Advantages
A Focus on Select Heparin-based Injectables
Lovenox/Clexane (enoxaparin)
Fragmin (dalteparin sodium)
Fraxiparine (nadroparin)
Innohep (tinzaparin)
Normiflo (ardeparin)
Clivarine (reviparin)
Non-Heparin Anticoagulant Injectables – An Overview
Arixtra (fondaparinux)
Angiomax (bivalirudin)
Argatroban/Novastan
4. THERAPEUTIC INDICATIONS
Venous/DVT Thrombosis Indications
Venous Thromboembolism
Deep Vein Thrombosis
Pulmonary Embolism
Orthopedic (Hip or Knee Replacement) Surgery
General Surgery
Cancer
Arterial Thrombosis Indications
Arterial Thrombosis
Acute Coronary Syndromes
Atrial Fibrillation
Unstable Angina
List of Approved Anticoagulants for Unstable Angina
Myocardial Infarction
Non ST-Segment Elevation MI
Percutaneous Transluminal Coronary Angioplasty (PTCA)
Heparin Induced Thrombocytopenia (HIT) Indications
Heparin Induced Thrombocytopenia with Thrombosis (HITTS)
Other Indications
Hemodialysis
5. PRODUCT INTRODUCTIONS/APPROVALS
FDA Approves Pradaxa Antidote Praxbind
CFDA Approves Bayer’s Xarelto
Raplixa Anticoagulant by MDCO Receives FDA Approval
Teva Launches Argatroban Injection in the US Market
BMS and Pfizer Announce Phase III Results of Apixaban
Boehringer Ingelheim Receives Priority Review by FDA for Idarucizumab BLA
FDA Grants Fast Track Designation to Perosphere’s PER977
FDA Approves Savaysa/Edoxaban
FDA Approves sNDA for Eliquis
USFDA Approves Pradaxa by Boehringer Ingelheim
EC Approves Expanded Indications of Xarelto
6. RECENT INDUSTRY ACTIVITY
Bayer Collaborates with Janssen on Extended Clinical Investigation of Xarelto
Bayer to Acquire Experimental Anticoagulant from Isis Pharmaceuticals
Akers Biosciences Receives Supply Order from NovoTek for PIFA Heparin PF4
Mylan Ireland to Acquire Arixtra Generic Rights from Aspen
Merus Labs Acquires Sintrom (acenocoumarol) from Novartis AG
CMC Biologics Signs Supply Agreement with Portola Pharmaceuticals
GlaxoSmithKline Divests Thrombosis Brands to Aspen
SQI Diagnostics Partners with Algorithme Pharma on Multiplex Heparin Assay
7. FOCUS ON SELECT GLOBAL PLAYERS
Abbott India Limited (India)
Aspen Holdings (South Africa)
Bayer Healthcare AG (Germany)
Boehringer Ingelheim (Germany)
Bristol-Myers Squibb Company (US)
Eisai Inc. (US)
GlaxoSmithKline Plc. (UK)
Mitsubishi Tanabe Pharma Corporation (Japan)
Pfizer, Inc. (US)
Sanofi S.A. (France)
Teva Pharmaceutical Industries Ltd. (Israel)
8. GLOBAL MARKET PERSPECTIVE
Table 7: World Recent Past, Current & Future Analysisfor Anticoagulants by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America,and Rest of World Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years2014 through 2020 (includes correspondingGraph/Chart)
Table 8: World Historic Review for Anticoagulants by Geographic Region/Country – US, Canada, Japan,Europe, Asia-Pacific, Latin America, and Rest ofWorld Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years2007 through 2013 (includes correspondingGraph/Chart)
Table 9: World 14-Year Perspective for Anticoagulantsby Geographic Region/Country – PercentageBreakdown of Dollar Sales for US, Canada, Japan,Europe, Asia-Pacific, Latin America, and Rest ofWorld Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
Table 10: World Recent Past, Current & FutureAnalysis for Oral Anticoagulants by Geographic Region/Country – US, Canada, Japan, Europe,Asia-Pacific, Latin America, and Rest of WorldMarkets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 11: World Historic Review for Oral Anticoagulantsby Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest ofWorld Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years2007 through 2013 (includes correspondingGraph/Chart)
Table 12: World 14-Year Perspective for Oral Anticoagulants by Geographic Region/Country -Percentage Breakdown of Dollar Sales for US,Canada, Japan, Europe, Asia-Pacific, Latin America,and Rest of World Markets for Years 2007, 2015 &2020 (includes corresponding Graph/Chart)
Table 13: World Recent Past, Current & FutureAnalysis for Injectable Anticoagulants by Geographic Region/Country – US, Canada, Japan, Europe,Asia-Pacific, Latin America, and Rest of WorldMarkets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2014through 2020 (includes corresponding Graph/Chart)
Table 14: World Historic Review for Injectable Anticoagulants by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America,and Rest of World Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years2007 through 2013 (includes correspondingGraph/Chart)
Table 15: World 14-Year Perspective for Injectable Anticoagulants by Geographic Region/Country -Percentage Breakdown of Dollar Sales for US,Canada, Japan, Europe, Asia-Pacific, Latin America,and Rest of World Markets for Years 2007, 2015 &2020 (includes corresponding Graph/Chart)
Table 16: World Recent Past, Current & FutureAnalysis for Injectable Anticoagulants by ProductSegment – Unfractionated Heparin and LowMolecular Weight Heparin Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Millionfor Years 2014 through 2020 (includescorresponding Graph/Chart)
Table 17: World Historic Review for Injectable Anticoagulants by Product Segment – UnfractionatedHeparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figuresin US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 18: World 14-Year Perspective for Injectable Anticoagulants by Product Segment – PercentageBreakdown of Dollar Sales for Unfractionated Heparinand Low Molecular Weight Heparin Marketsfor Years 2007, 2015 & 2020 (includescorresponding Graph/Chart)
Table 19: World Recent Past, Current & FutureAnalysis for Unfractionated Heparin by Geographic Region/Country – US, Canada, Japan, Europe,Asia-Pacific, Latin America, and Rest of WorldMarkets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 20: World Historic Review for UnfractionatedHeparin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, andRest of World Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2007through 2013 (includes corresponding Graph/Chart)
Table 21: World 14-Year Perspective for Unfractionated Heparin by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan,Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 22: World Recent Past, Current & FutureAnalysis for Low Molecular Weight Heparin byGeographic Region/Country – US, Canada, Japan,Europe, Asia-Pacific, Latin America, and Rest ofWorld Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2014 through2020 (includes corresponding Graph/Chart)
Table 23: World Historic Review for Low MolecularWeight Heparin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America,and Rest of World Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years2007 through 2013 (includes correspondingGraph/Chart)
Table 24: World 14-Year Perspective for LowMolecular Weight Heparin by Geographic Region/Country – Percentage Breakdown of Dollar Salesfor US, Canada, Japan, Europe, Asia-Pacific,Latin America, and Rest of World Markets forYears 2007, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET
1. THE UNITED STATES
A. Market Analysis
Key Statistics
US: The Largest Market for Anti-Coagulants
A List of FDA Approved Anticoagulants
Atrial Fibrillation – A Key Risk Factor
Rapidly Ageing Demographics Drive Growth in the Anticoagulants Market
Table 25: North American Aging Population byAge Group: 1975-2050 (includes corresponding Graph/Chart)
Surge in CVD Incidence – Major Growth Factor
Table 26: CVD in the US: CardiovascularDisease Prevalence in Adults by Gender &Age Group (includes correspondingGraph/Chart)
Table 27: CVD in the US: CardiovascularDisease Incidence by Gender & AgeGroup (per 1,000 Adults) (includescorresponding Graph/Chart)
Table 28: Leading Causes of CVD Fatalities inthe US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure,Stroke, and Others (includes corresponding Graph/Chart)
Lack of Public Health Funding
Table 29: US Healthcare Spending byTherapeutic Area (2014): Percentage Share Breakdown of Expenditure for VariousTherapeutic Areas (includes corresponding Graph/Chart)
US Heparin Market
Heparin Trade Statistics
Table 30: The US Exports of Heparin & its Salts; Human/Animal Substances for TherapeuticUses (2014 & 2013): Percentage ShareBreakdown of Export Value of LeadingDestination Countries (includes corresponding Graph/Chart)
Table 31: The US Imports of Heparin & itsSalts; Human/Animal Substances forTherapeutic Uses (2014 & 2013): PercentageShare Breakdown of Import Value of Leading Countries of Origin (includes corresponding Graph/Chart)
Product Introductions/Approvals
Strategic Corporate Developments
Select Key Players
B. Market Analytics
Table 32: The US Recent Past, Current & Future Analysis for Anticoagulants by Product Type -Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years2014 through 2020 (includes corresponding Graph/Chart)
Table 33: The US Historic Review for Anticoagulantsby Product Type - Oral Anticoagulants andInjectable Anticoagulants (Unfractionated Heparinand Low Molecular Weight Heparin) Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2007 through2013 (includes corresponding Graph/Chart)
Table 34: The US 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
2. CANADA
A. Market Analysis
Heparin Trade Statistics
Table 35: Canadian Exports of Heparin & itsSalts; Human/Animal Substances for Therapeutic Uses (2014 & 2013): Percentage ShareBreakdown of Export Value of LeadingDestination Countries (includescorresponding Graph/Chart)
Table 36: Canadian Imports of Heparin & its Salts; Human/Animal Substances for Therapeutic Uses (2014 & 2013): Percentage Share Breakdown of Import Value of Leading Countries of Origin(includes corresponding Graph/Chart)
B. Market Analytics
Table 37: Canadian Recent Past, Current & Future Analysis for Anticoagulants by Product Type -Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years2014 through 2020 (includes corresponding Graph/Chart)
Table 38: Canadian Historic Review for Anticoagulantsby Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 39: Canadian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
3. JAPAN
A. Market Analysis
Graying Population Spurs Growth of Anticoagulants
Table 40: Japanese Elderly (65+ Years)Population: 2000-2020 (includescorresponding Graph/Chart)
Table 41: Aging Population Growth (%) inJapan: 2015
P (includes corresponding Graph/Chart)
Select Key Players
B. Market Analytics
Table 42: Japanese Recent Past, Current &Future Analysis for Anticoagulants by ProductType - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin andLow Molecular Weight Heparin) MarketsIndependently Analyzed with Annual SalesFigures in US$ Million for Years 2014 through2020 (includes corresponding Graph/Chart)
Table 43: Japanese Historic Review for Anticoagulantsby Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includescorresponding Graph/Chart)
Table 44: Japanese 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
4. EUROPE
A. Market Analysis
Europe: A Major Anti-Coagulant Market
Differential Uptake of NOACs by European Countries
Table 45: European Percentage Uptake ofNOACs by Country: 2014 (includescorresponding Graph/Chart)
Increasing Aging Population Boosts Demand
Table 46: Life Expectancy at 65 Years forSelect Countries in Europe: 2012 (includes corresponding Graph/Chart)
Table 47: European Population by AgeGroup (2014): Percentage Share Breakdown ofAge groups 0-19, 20-39, 40-59, 60-79, and 80+ (includes corresponding Graph/Chart)
LMWH: Dominant Heparin Segment in Europe
B. Market Analytics
Table 48: European Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain,Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2014 through 2020(includes corresponding Graph/Chart)
Table 49: European Historic Review forAnticoagulants by Geographic Region/Country -France, Germany, Italy, UK, Spain, Russia,and Rest of Europe Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 50: European 14-Year Perspective for Anticoagulants by Geographic Region/Country -Percentage Breakdown of Dollar Sales forFrance, Germany, Italy, UK, Spain, Russia,and Rest of Europe Markets for Years 2007,2015 & 2020 (includes correspondingGraph/Chart)
Table 51: European Recent Past, Current &Future Analysis for Anticoagulants by ProductType - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin andLow Molecular Weight Heparin) MarketsIndependently Analyzed with Annual SalesFigures in US$ Million for Years 2014 through2020 (includes corresponding Graph/Chart)
Table 52: European Historic Review forAnticoagulants by Product Type - OralAnticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 53: European 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
4a. FRANCE
A. Market Analysis
Sanofi S.A. – A Key Player
B. Market Analytics
Table 54: French Recent Past, Current & Future Analysis for Anticoagulants by Product Type -Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets Independently Analyzedwith Annual Sales Figures in US$ Million forYears 2014 through 2020 (includescorresponding Graph/Chart)
Table 55: French Historic Review forAnticoagulants by Product Type - OralAnticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 56: French 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
4b. GERMANY
A. Market Analysis
Product Launches
Strategic Corporate Developments
Focus on Select Players
B. Market Analytics
Table 57: German Recent Past, Current & Future Analysis for Anticoagulants by Product Type -Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets Independently Analyzedwith Annual Sales Figures in US$ Million forYears 2014 through 2020 (includescorresponding Graph/Chart)
Table 58: German Historic Review for Anticoagulantsby Product Type - Oral Anticoagulants andInjectable Anticoagulants (Unfractionated Heparinand Low Molecular Weight Heparin) Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2007 through2013 (includes corresponding Graph/Chart)
Table 59: German 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
4c. ITALY
Market Analysis
Table 60: Italian Recent Past, Current & FutureAnalysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2014 through 2020(includes corresponding Graph/Chart)
Table 61: Italian Historic Review for Anticoagulantsby Product Type - Oral Anticoagulants andInjectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2007through 2013 (includes correspondingGraph/Chart)
Table 62: Italian 14-Year Perspective forAnticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A. Market Analysis
Stroke Statistics – Opportunity Indicator for Anticoagulants
NICE Guidelines Promote NOAC Usage
Strategic Corporate Development
GlaxoSmithKline Plc. – A Key Player
B. Market Analytics
Table 63: The UK Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years2014 through 2020 (includes corresponding Graph/Chart)
Table 64: The UK Historic Review forAnticoagulants by Product Type - OralAnticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 65: The UK 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
4e. SPAIN
Market Analysis
Table 66: Spanish Recent Past, Current & Future Analysis for Anticoagulants by Product Type -Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years2014 through 2020 (includes corresponding Graph/Chart)
Table 67: Spanish Historic Review for Anticoagulantsby Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 68: Spanish 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
4f. RUSSIA
Market Analysis
Table 69: Russian Recent Past, Current & Future Analysis for Anticoagulants by Product Type -Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2014 through 2020(includes corresponding Graph/Chart)
Table 70: Russian Historic Review for Anticoagulantsby Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includescorresponding Graph/Chart)
Table 71: Russian 14-Year Perspective for Anticoagulants by Product Type -Percentage Breakdown of Dollar Sales forOral Anticoagulants and InjectableAnticoagulants (Unfractionated Heparin andLow Molecular Weight Heparin) Markets forYears 2007, 2015 & 2020 (includescorresponding Graph/Chart)

4g. REST OF EUROPE
A. Market Analysis
Strategic Corporate Development
B. Market Analytics
Table 72: Rest of European Recent Past,Current & Future Analysis for Anticoagulantsby Product Type - Oral Anticoagulants andInjectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2014through 2020 (includes correspondingGraph/Chart)
Table 73: Rest of European Historic Review for Anticoagulants by Product Type - OralAnticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 74: Rest of European 14-Year Perspectivefor Anticoagulants by Product Type -Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets for Years 2007,2015 & 2020 (includes correspondingGraph/Chart)
5. ASIA-PACIFIC
A. Market Analysis
Highly Populated Asian Countries Offer Significant Growth Opportunities
Table 75: Population Statistics in SelectAsian Countries & Percentage of PopulationAged Above 65 Years (includescorresponding Graph/Chart)
B. Market Analytics
Table 76: Asia-Pacific Recent Past, Current &Future Analysis for Anticoagulants by Geographic Region/Country - China, India, and Rest ofAsia-Pacific Markets Independently Analyzedwith Annual Sales Figures in US$ Million forYears 2014 through 2020 (includescorresponding Graph/Chart)
Table 77: Asia-Pacific Historic Review for Anticoagulants by Geographic Region/Country -China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2007 through2013 (includes corresponding Graph/Chart)
Table 78: Asia-Pacific 14-Year Perspective for Anticoagulants by Geographic Region/Country -Percentage Breakdown of Dollar Sales for China,India, and Rest of Asia-Pacific Markets for Years2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 79: Asia-Pacific Recent Past, Current &Future Analysis for Anticoagulants by ProductType - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin andLow Molecular Weight Heparin) MarketsIndependently Analyzed with Annual SalesFigures in US$ Million for Years 2014 through2020 (includes corresponding Graph/Chart)
Table 80: Asia-Pacific Historic Review for Anticoagulants by Product Type - OralAnticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 81: Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
5a. CHINA
A. Market Analysis
Favorable Reimbursement for NOACs
LMWH – The leading Heparin Segment
Table 82: Chinese Import & Export Volumesand Values of Heparin & its Salts (2013, 2014 & 2015): Total Import Volume & Total ExportVolume (in Kg); and Total Import Value &Total Export Value (in US$)
Product Approval
Strategic Corporate Development
B. Market Analytics
Table 83: Chinese Recent Past, Current & Future Analysis for Anticoagulants by Product Type -Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets Independently Analyzedwith Annual Sales Figures in US$ Million forYears 2014 through 2020 (includescorresponding Graph/Chart)
Table 84: Chinese Historic Review forAnticoagulants by Product Type - OralAnticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 85: Chinese 14-Year Perspective for Anticoagulants by Product Type -Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets for Years 2007,2015 & 2020 (includes correspondingGraph/Chart)
5b. INDIA
A. Market Analysis
Abbott India Limited – A Key Player
B. Market Analytics
Table 86: Indian Recent Past, Current & FutureAnalysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2014 through 2020(includes corresponding Graph/Chart)
Table 87: Indian Historic Review for Anticoagulantsby Product Type - Oral Anticoagulants andInjectable Anticoagulants (Unfractionated Heparinand Low Molecular Weight Heparin) Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2007 through2013 (includes corresponding Graph/Chart)
Table 88: Indian 14-Year Perspective forAnticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
5c. REST OF ASIA-PACIFIC
Market Analysis
Table 89: Rest of Asia-Pacific Recent Past,Current & Future Analysis for Anticoagulantsby Product Type - Oral Anticoagulants andInjectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2014through 2020 (includes correspondingGraph/Chart)
Table 90: Rest of Asia-Pacific Historic Reviewfor Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 91: Rest of Asia-Pacific 14-YearPerspective for Anticoagulants by ProductType - Percentage Breakdown of DollarSales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin andLow Molecular Weight Heparin) Markets forYears 2007, 2015 & 2020 (includescorresponding Graph/Chart)
6. LATIN AMERICA
Market Analysis
Table 92: Latin American Recent Past, Current &Future Analysis for Anticoagulants by Geographic Region/Country - Brazil and Rest of Latin American Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2014through 2020 (includes correspondingGraph/Chart)
Table 93: Latin American Historic Review for Anticoagulants by Geographic Region/Country -Brazil and Rest of Latin American Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2007 through2013 (includes corresponding Graph/Chart)
Table 94: Latin American 14-Year Perspectivefor Anticoagulants by Geographic Region/Country -Percentage Breakdown of Dollar Sales for Braziland Rest of Latin American Markets for Years2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 95: Latin American Recent Past,Current & Future Analysis for Anticoagulantsby Product Type - Oral Anticoagulants andInjectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2014through 2020 (includes correspondingGraph/Chart)
Table 96: Latin American Historic Review for Anticoagulants by Product Type - OralAnticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 97: Latin American 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulantsand Injectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets for Years 2007, 2015 & 2020(includes corresponding Graph/Chart)
6a. BRAZIL
Market Analysis
Table 98: Brazilian Recent Past, Current &Future Analysis for Anticoagulants by ProductType - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin andLow Molecular Weight Heparin) MarketsIndependently Analyzed with Annual SalesFigures in US$ Million for Years 2014through 2020 (includes correspondingGraph/Chart)
Table 99: Brazilian Historic Review forAnticoagulants by Product Type - OralAnticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 100: Brazilian 14-Year Perspective for Anticoagulants by Product Type -Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets for Years2007, 2015 & 2020 (includes corresponding Graph/Chart)
6b. REST OF LATIN AMERICA
Market Analysis
Table 101: Rest of Latin American Recent Past,Current & Future Analysis for Anticoagulantsby Product Type - Oral Anticoagulants andInjectable Anticoagulants (UnfractionatedHeparin and Low Molecular Weight Heparin)Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2014through 2020 (includes correspondingGraph/Chart)
Table 102: Rest of Latin American HistoricReview for Anticoagulants by Product Type -Oral Anticoagulants and InjectableAnticoagulants (Unfractionated Heparin andLow Molecular Weight Heparin) MarketsIndependently Analyzed with Annual SalesFigures in US$ Million for Years 2007through 2013 (includes correspondingGraph/Chart)
Table 103: Rest of Latin American 14-YearPerspective for Anticoagulants by ProductType - Percentage Breakdown of DollarSales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin andLow Molecular Weight Heparin) Markets forYears 2007, 2015 & 2020 (includescorresponding Graph/Chart)
7. REST OF WORLD
A. Market Analysis
Teva Pharmaceutical Industries Ltd – A Key Player (Israel)
B. Market Analytics
Table 104: Rest of World Recent Past, Current &Future Analysis for Anticoagulants by ProductType - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includescorresponding Graph/Chart)
Table 105: Rest of World Historic Review for Anticoagulants by Product Type - OralAnticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets IndependentlyAnalyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2013(includes corresponding Graph/Chart)
Table 106: Rest of World 14-Year Perspectivefor Anticoagulants by Product Type -Percentage Breakdown of Dollar Sales forOral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low MolecularWeight Heparin) Markets for Years 2007,2015 & 2020 (includes correspondingGraph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 51 (including Divisions/Subsidiaries - 59)
The United States (25)
Canada (1)
Japan (3)
Europe (13)
- France (1)
- Germany (3)
- The United Kingdom (4)
- Rest of Europe (5)
Asia-Pacific (Excluding Japan) (12)
Africa (1)
Middle East (4)

★調査レポート[抗凝血薬(経口抗凝血薬、注射用抗凝血薬、未分画ヘパリン、低分子ヘパリン)の世界市場]販売に関する免責事項
★調査レポート[抗凝血薬(経口抗凝血薬、注射用抗凝血薬、未分画ヘパリン、低分子ヘパリン)の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆